Hey there! Welcome!
Get updated on
stem cell
stem cell
stem cell
Top Picks

calendar
14 Jul, 26
dot
link
ESHRE 2026
Key highlights of the sessions on fertility preservation presented at ESHRE from 5th to 8th July 2026 in London, UK.

calendar
14 Jul, 26
dot
link
ESHRE 2026
Key highlights of the sessions on global and socio-cultural aspects of infertility presented at ESHRE from 5th to 8th July 2026 in London, UK.

calendar
28 Jul, 26
dot
link
JAMA Pediatr.
  • Nearly half of children with obesity had Metabolically Healthy Obesity (MHO) at baseline.
  • By age 30 years, risk of type 2 diabetes, hypertension, and dyslipidemia were substantially higher in both MHO and metabolically unhealthy obesity (MUO).
  • A reduction in body mass index (BMI) z score ≥0.25 markedly lowered cardiometabolic risk.
  • Weight management should be offered regardless of metabolic status.

calendar
28 Jul, 26
dot
link
Hypertension.
  • Impact of weight gain patterns across successive pregnancies on long-term maternal cardiometabolic (CM) health assessed (N=58333)
  • 5.9% developed CM disease within 4 yrs postpartum, high gestational weight gain (≥+1 Z score; ~19.4 kg at 40 wks in normal-weight women) during the 1st pregnancy raised risk by 29%
  • Risk stayed high after 2nd pregnancy (30%), preventing excessive 1st pregnancy weight gain is essential.

calendar
27 Jul, 26
dot
link
Respir Med
  • Associations between relative muscle strength (RMS) and peak expiratory flow (PEF) in middle-aged and older adults were studied
  • Higher RMS was linked to better PEF, higher predicted PEF%, slower respiratory decline, and lower odds of impaired expiratory performance
  • Associations plateaued at RMS 1.8–2.0 and were stronger in males and smokers, supporting RMS as a simple marker of respiratory health during aging.

calendar
23 Jul, 26
dot
link
Diabetes Res Clin Pr...
  • A meta-analysis of 22 RCTs (n=29,023) in adults with T2DM or overweight/obesity showed that tirzepatide significantly reduced major adverse cardiovascular events (MACE; OR:0.87) & all-cause mortality (OR:0.84)
  • The MACE odds lowered by 2.8% per 1 mg dose increase of tirzepatide, indicating a dose-response effect
  • No significant benefit was seen for individual MACE components or HF hospitalization.

calendar
24 Jul, 26